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Active case finding (ACF) may be valuable in tuberculosis (TB) control, but questions remain
about its optimum implementation in different settings. For example, smear microscopy
misses up to half of TB cases, yet is cheap and detects the most infectious TB cases. What,
then, is the incremental value of using more sensitive and specific, yet more costly, tests
such as Xpert MTB/RIF in ACF in a high-burden setting?
Methods and findings
We constructed a dynamic transmission model of TB, calibrated to be consistent with an
urban slum population in India. We applied this model to compare the potential cost and
impact of 2 hypothetical approaches following initial symptom screening: (i) ‘moderate accu-
racy’ testing employing a microscopy-like test (i.e., lower cost but also lower accuracy) for
bacteriological confirmation and (ii) ‘high accuracy’ testing employing an Xpert-like test
(higher cost but also higher accuracy, while also detecting rifampicin resistance). Results
suggest that ACF using a moderate-accuracy test could in fact cost more overall than using
a high-accuracy test. Under an illustrative budget of US$20 million in a slum population of 2
million, high-accuracy testing would avert 1.14 (95% credible interval 0.75–1.99, with p =
0.28) cases relative to each case averted by moderate-accuracy testing. Test specificity is a
key driver: High-accuracy testing would be significantly more impactful at the 5% signifi-
cance level, as long as the high-accuracy test has specificity at least 3 percentage points
greater than the moderate-accuracy test. Additional factors promoting the impact of high-
accuracy testing are that (i) its ability to detect rifampicin resistance can lead to long-term
cost savings in second-line treatment and (ii) its higher sensitivity contributes to the overall
cases averted by ACF. Amongst the limitations of this study, our cost model has a narrow
focus on the commodity costs of testing and treatment; our estimates should not be taken
as indicative of the overall cost of ACF. There remains uncertainty about the true specificity
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of tests such as smear and Xpert-like tests in ACF, relating to the accuracy of the reference
standard under such conditions.
Conclusions
Our results suggest that cheaper diagnostics do not necessarily translate to less costly
ACF, as any savings from the test cost can be strongly outweighed by factors including
false-positive TB treatment, reduced sensitivity, and foregone savings in second-line treat-
ment. In resource-limited settings, it is therefore important to take all of these factors into
account when designing cost-effective strategies for ACF.
Author summary
Why was this study done?
• Active case finding (ACF) is a strategy for reducing the burden of tuberculosis (TB) that
aims to identify and treat TB cases in the community, as rapidly as possible.
• However, because ACF can be very resource-intensive, it is important to understand
how best to conduct it, in the most cost-efficient way.
• Concentrating on the tests used to diagnose TB, we hypothesised that cheaper tests,
although less accurate than more costly tests, would be important in bringing down the
overall cost of ACF.
What did the researchers do and find?
• Using a mathematical model of TB in urban slums in India, we simulated the cost and
impact of an ACF intervention over the next 15 years.
• Contrary to our initial hypothesis, we found that the use of cheaper diagnostic tests with
lower accuracy can in fact increase, not decrease, the overall cost of ACF.
• The reason is that the cost of a test can be outweighed by the costs of treatment, specifi-
cally false-positive (unnecessary) TB treatment, and second-line treatment for drug-
resistant TB; cheaper tests would also have lower impact overall, as a result of their
lower sensitivity.
What do these findings mean?
• Our findings show how cheaper diagnostic tests may represent a false economy in ACF,
i.e., leading to larger intervention costs overall, if they are also associated with reduced
performance in ruling out TB.
• Those implementing ACF in resource-limited, high-burden settings should consider all
of these factors in their planning, and not just the cost of the test.
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Introduction
Tuberculosis (TB) remains a major concern for global health, with 10.4 million incident cases
globally in 2017 and approximately 1.3 million deaths [1]. The End TB Strategy calls for a
reduction in incidence of 90% by 2035 [2]; to reach this target, it will be necessary to accelerate
the rate at which TB cases are diagnosed and initiated on treatment [2]. Active case finding
(ACF) is one way of doing so: Modelling suggests that ACF could be cost-effective under cer-
tain cost thresholds, particularly over longer (>10 years) time horizons [3] However, direct
evidence for the potential impact of such measures in practice is limited [4], including in set-
tings like India, the country with the world’s largest TB burden, which alone has an estimated
26% of the 3.6 million estimated ‘missing cases’ [1].
In response to these challenges, a key component in India’s 2017 National Strategic Plan for
TB Elimination is the need to perform intensive, sustained ACF in specific populations such as
urban slums, which are known to have a greater TB burden than the general population [5]. In
general, ACF in these and other settings employs screening for symptoms suggestive of TB, fol-
lowed by bacteriological testing. The latter is often performed using molecular tools such as
Xpert MTB/RIF (hereafter referred to as ‘Xpert’), a cartridge-based nucleic acid amplification
test. More recently developed, the ‘Ultra’ diagnostic platform offers higher sensitivity than
Xpert, but at the expense of lower specificity [6]. In the present work, we concentrate on the
deployment of Xpert. Key advantages of Xpert are that (i) it is more sensitive than the conven-
tionally used smear microscopy, which can miss up to half of pulmonary TB cases [7] and (ii)
it offers detection of rifampicin resistance at the point of TB diagnosis [1,8], thus allowing the
timely initiation of second-line treatment. However, those cases detectable through smear
microscopy tend to be the most infectious [9], and smear microscopy is considerably cheaper
than Xpert. Therefore, the use of smear microscopy may achieve substantial epidemiological
impact, at a lower cost.
Could smear-based ACF be more cost-effective than Xpert-based ACF, in settings such as
India? What are the benefits of using Xpert in comparison to smear microscopy, and vice
versa? Our scope is not simply yield (defined as the proportion of positive cases identified), a
major focus of operational research, but also potential epidemiological impact, taking into
account the potential transmission implications of ACF. In line with India’s National Strategic
Plan, we model case-finding efforts in conditions typical of urban slums using a transmission
model combined with a simple costing approach. Building on previous modelling analyses of
ACF [10,11], in this work we focus on both the specificity and sensitivity of the diagnostic
strategy employed in ACF.
Methods
Transmission model
We developed a dynamic transmission model of TB, illustrated in Fig 1 and described in fur-
ther technical detail in S1 Text. The model captures key features in the natural history of TB,
including asymptomatic but infectious disease, smear status, TB mortality, and spontaneous
cure. The model focuses on pulmonary TB and disregards extrapulmonary TB, assuming ACF
to focus on the former. Amongst those with TB (indicated by the orange box in Fig 1), we
assumed that smear-negative pulmonary TB cases are, on average, 20% as infectious as smear-
positive ones [9] (see Table 1 for model parameters). We incorporated ‘passive’ TB service
delivery, including the split between public and private sectors that is a major feature of the
health system in India [12]. Additionally, the model also distinguishes drug-susceptible TB
(DS-TB) and drug-resistant TB (DR-TB), the latter including both rifampicin-resistant and
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multi-drug-resistant forms of TB. Although DR-TB only accounts for approximately 5% of the
TB burden in India, it also consumes a disproportionate amount of the TB budget due to the
high cost of second-line treatment [1]. In the model, we account for the delay in recognition of
DR-TB as a result of missed opportunities for drug sensitivity testing, as well as the potential
impact of Xpert-based ACF in reducing this delay.
We separately simulated the dynamics of a non-TB symptomatic (NTS) population, i.e.,
individuals who would be eligible for a TB diagnosis based on the presence of TB-like symp-
toms, but who do not have TB. This population is necessary for tracking the overall number of
diagnostic tests being conducted during the case-finding intervention, as well as the unneces-
sary treatment of false-positive TB [13].
Fig 1. Schematic illustration of the model. The tuberculosis (TB) transmission model distinguishes TB by smear status and by symptom status. Upon developing
symptoms, symptomatic individuals seek care through either the private or public sectors (‘passive’ TB services) after a certain delay, estimated to match data in Table 2.
Although not shown here for clarity, the model captures these sectors separately, including the lower standard of TB care in the private sector (see S1 Text for full model
details). Those successfully diagnosed initiate TB treatment; we assume that 15% of diagnoses in the public sector are conducted with Xpert, the remainder by
microscopy. All those lost from the TB care cascade, whether because of missed diagnosis, pre-treatment loss to follow-up, or failed treatment, temporarily disengage
from care-seeking, before once again seeking care after a given delay. Compartments shown in orange denote the effect of an active case finding (ACF) intervention on
this ‘passive’ system; we assume that ACF consists of initial symptom screening, followed by microbiological confirmation. Meanwhile, the separate compartments on
the right represent a subset of the general population that may be detected by the ACF intervention (represented by the orange compartments) because they have TB-
like symptoms, but without TB: These may include, for example, individuals with chronic obstructive pulmonary disease, bronchitis, and other lung conditions. They
incur a cost to the health system for diagnosis and—if they are mistakenly diagnosed with TB—a cost in false-positive treatment. The number incorrectly identified as
having TB is dependent on the specificity of both the screening and confirmatory stages. Finally, at any stage individuals may die of natural causes or of TB (in the
diseased compartments) or recover spontaneously. For simplicity, these transitions are not shown in the figure (see S1 Text for full model details).
https://doi.org/10.1371/journal.pmed.1003456.g001
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Table 1. List of model parameters.




Infection rate, smear-positive DS-TB βDS 9.10 years
−1 (7.35–
10.70)
Fitted to epidemiological data (Table 2)
Infection rate, smear-positive DR-TB βMDR 5.19 years
−1 (4.12–
6.26)
Relative infectiousness, smear-negative versus smear-positive ε 0.2 (0.1–0.3) [9]
Rate of progression to active disease from latency a 0.0005–0.0015 [38]
Proportion of infections being ‘fast’ progressors to active disease pFast 0.05–0.15 [39]
Per capita rate of initial care-seeking upon first developing symptoms rCS 0.73 years−1 (0.57–
0.91)
Fitted: corresponds to a mean initial delay of over
a year
Per capita rate of repeat care-seeking rð2Þcs 12 years
−1 (9–15) Assumption: corresponds to a mean delay of 1–6
weeks
Per capita rate of smear conversion Symptomatic TB m0 0.71 years−1 (0.40–
1.04)
Fitted to prevalence survey data (Table 2)
Asymptomatic TB m1 0.63 years−1 (0.62–
0.64)
Per capita rate of symptom development Smear-positive TB e0 1.24 years−1 (1.02–
1.65)
Smear-negative TB e1 2.37 years−1 (1.90–
3.05)
Proportion of prevalent TB cases that are smear-positive ω+ 0.6 (0.5–0.7) [1]
Per capita rate of relapse After treatment
completion
r1 0.032 years−1 (0.024–
0.04)
[38]






Per capita rate of spontaneous recovery γ 0.1667 years−1
(0.1250–0.2083)
[38]: together, yielding a 50% case fatality rate over
3 years of untreated TB
Per capita rate of mortality, untreated TB μTB 0.1667 years−1
(0.1250–0.2083)
Proportion reduction in susceptibility to reinfection owing to previous infection ρ 0.21 (0.15–0.25) [40]
Per capita background mortality rate μ 0.0152 years−1 [38]: corresponds to a mean life expectancy of 66
years
Per capita birth rate b 0.0682 [41]: adjusted to yield 2.4% annual population
growth from 1970
Diagnosis (routine TB services, in absence of ACF)
Proportion seeking care from private sector p1 0.5 (0.4–0.6) Assumption, consistent with [12]
Proportion correctly diagnosed per provider visit Public sector pðDxÞ0 0.83 (0.81–0.85) [42]
Private sector pðDxÞ1 0.7 (0.6–0.8) Assumption
Proportion of diagnoses successfully initiating
treatment
First-line, public sector pðTxÞ0 0.88 (0.85–0.91) Aggregated for first- and second-line [42]
First-line, private sector pðTxÞ1 0.7 (0.6–0.8) Assumption
Second-line, public only pðTx2Þ0 0.88 (0.85–0.91) Aggregated for first- and second-line [42]
Proportion of TB recognised as DR-TB at point of diagnosis (public only�) pDST 0.12 (0.08–0.20) [22]
Treatment
Per capita rate of regimen completion First-line dTxFL 2 years−1 [1,3]: corresponds to a duration of 6 months
Second-line dTxSL 0.5 years−1 [1]: corresponds to a duration of 2 years
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Model calibration
The model described above was calibrated to annual risk of Mycobacterium tuberculosis infec-
tion and prevalence estimates representative of urban slums in India (Table 2). To inform
model parameters for symptom onset from asymptomatic stages, and for progression of smear
status with developing disease, we drew from a prevalence survey in Chennai [5]. In particular,
we calibrated the model to the proportion of prevalent TB cases that are symptomatic and the
proportion smear-positive amongst those who had not yet presented for care, stratified by
symptom status (Table 2).
Uncertainty was estimated using Latin hypercube sampling to sample model parameters
from their respective ranges (10,000 samples) and simulating the model to 2018, as described
in S1 Text. Parameter sets were accepted in the sampling if they provided model projections
that fell within the calibration target ranges, while the rest were rejected.
Table 1. (Continued)
Parameter Symbol Value (95% credible
interval)
Source/notes
Proportion second-line treatment success (public only�) c2 0.46 (0.44–0.5) [1,3]
Amongst DR-TB cases failing first-line treatment, proportion successfully
transferred onto second-line treatment (public only�)
pSL 0.88 (0.85–0.92) Assumption
Rate of DR-TB acquisition amongst DS-TB cases on first-line treatment rMDR 0.01 years−1 [1,38]
Active case finding
High-accuracy test performance (consistent with
available data for Xpert)
Sensitivity (smear-positive
TB)
s1 1 Assumption (at least as sensitive as smear)
Sensitivity (smear-
negative TB)
s0 0.7 (0.6–0.8) [43,44]
Specificity σ 0.99 (0.90–1.0) [45]��
Per capita rate of
performing diagnostic test
dDx 52 years−1 We assume 1 week for sample collection,
transportation, and analysis
Proportion of TB
recognised as DR-TB at
point of diagnosis
pDSTA 0.95 (0.90–0.97) [8]
Moderate-accuracy test performance (consistent
with available data for smear)
Sensitivity (smear-positive
TB)




Specificity σ 0.98 (0.93–1.0) [45]��
Per capita rate of
performing diagnostic test
dDx 52 years−1 We assume 1 week for sample collection,
transportation, and analysis
Symptom screening (any TB symptom) Sensitivity s 0.70 (0.58–0.82) [14]
Specificity��� σ 0.61 (0.35–0.87) [14]
Per capita rate of
performing symptom
screening
dsx 365 years−1 Assumption: corresponds to 1 day
�We assume that all DR-TB management occurs in the public, not private, sector.
��In the parameter sampling, we adopt only those joint parameter sets in which Xpert specificity is greater than that of smear.
���The size of the non-TB symptomatic (NTS) population was calculated using the specificity of the symptom screening method used (see S1 Text for full model
specifications). For a strategy screening for ‘any TB symptom’, the size of the NTS population would therefore be 39% of the size of the population in which TB
dynamics are modelled.
ACF, active case finding; DR-TB, drug-resistant tuberculosis; DS-TB, drug-susceptible tuberculosis; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003456.t001
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Intervention
Using the calibrated model, we simulated an ACF algorithm using symptom screening fol-
lowed by a confirmatory microbiological test. We assumed that all TB diagnoses through ACF
would be microbiologically confirmed, i.e., we assumed that there is no role for presumptive
clinical diagnosis in ACF. For the screening stage, we modelled the use of symptom screening,
with individuals reporting any symptom suggestive of TB deemed eligible for microbiological
confirmation. For the sensitivity and specificity of this approach for TB, we drew from a recent
meta-analysis of screening approaches [14]. We also performed sensitivity analyses (described
below) under an alternative screening approach: identifying those with prolonged cough,
rather than any TB symptom (with prolonged cough screening having higher specificity but
lower sensitivity than ‘any TB symptom’).
For the confirmatory test, we distinguished 2 types of strategy: a ‘moderate accuracy’ strat-
egy, using a confirmatory test with performance and cost consistent with smear microscopy,
and a ‘high accuracy’ strategy, using a confirmatory test with performance and cost consistent
with Xpert (see Table 1 for parameters). The reason for these designations is that—although
there exists data from clinical trials on the performance of smear microscopy and Xpert—
there is currently little evidence for characteristics such as the specificity of either test in real-
world conditions. In particular, test specificity is often assessed against culture as a reference
standard and thus does not address how to interpret smear-positive, culture-negative cases
that nonetheless show clear signs of having TB [15,16]. We do not address the important ques-
tion of how reference standards might be improved to meet these challenges. Instead, our anal-
ysis casts light on which types of uncertainty are most critical for future studies to address in
strategic planning for ACF activities. Consistent with the capabilities of smear microscopy and
molecular tests such as Xpert, we assumed that the high-accuracy test can detect rifampicin
resistance at the same time as detecting TB, while the moderate-accuracy test cannot. We
assumed that all individuals recognised as having rifampicin resistance are immediately initi-
ated on second-line therapy, while those with unrecognised rifampicin resistance are only
switched to second-line therapy after failing first-line treatment.





Slum prevalence (per 100,000 population) of culture-
positive TB, as of 2012
432 (341–527) Drawn from [5], using prevalence of culture-positive TB (259 per 100,000), and
inferring the slum prevalence from the univariate odds ratio of culture-positive TB in
slum versus non-slum settings (2.3), together with an assumed slum size of 20% of the
urban population
Slum ARTI, as of 2006 2.5% (1.9%–3.1%) [46] and Chadha VK. Personal communication. “Unpublished data, First round of
zonal ARTI surveys in India, 2000–2003”
Proportion of TB incidence that is DR-TB as of 2018 5% (4%–6%) [47]
Proportion of prevalent TB having any TB symptoms 70% (58%–82%) By definition, same as assumed value of sensitivity of symptom screening (Table 1)
Proportion of prevalent TB that is







DR-TB includes both rifampicin-resistant and multi-drug-resistant forms of TB. Although largely drawn from a prevalence survey in Chennai, South India [5], these
data are broadly consistent with prevalence surveys in urban settings elsewhere in India [48].
ARTI, annual risk of tuberculosis infection; DR-TB, drug-resistant tuberculosis; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003456.t002
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We considered ‘sensitivity’ as the proportion of TB cases that yield a positive microbiolog-
ical result under a given test, and likewise ‘specificity’ as the proportion of individuals without
TB who yield a negative microbiological result. Moreover, we assumed that all smear-positive
cases test positive through a smear-like test, and that no smear-negative cases do (i.e., sensitivi-
ties of 1 and 0, respectively). This is a simplification for model purposes: We also performed a
sensitivity analysis under alternative assumptions, where smear status is associated with a
given probability of diagnosis.
We simulated the intervention at different levels of coverage to run from 2020 to 2035,
scaled up linearly over the first 4 years (2020–2023), ultimately to screen a given proportion of
the population per year. We assumed for simplicity that this proportion is selected at random
from the slum population each year. The impact of ACF was measured as the percentage
reduction in cumulative incidence between 2020 and 2035. Finally, we calculated the incre-
mental costs of the intervention relative to a baseline of status quo, i.e., current standards of
TB care continued indefinitely, without ACF.
Economic evaluation
We focus on the programmatic perspective, i.e., considering only costs borne by the TB pro-
gramme, and ignoring broader societal costs. The model accounts for ‘passive’ TB services, i.e.,
those routine services (diagnosis and treatment, both first- and second-line) independent of
ACF, and contingent on patients presenting for care. Since these services could be lowered by
the rollout of ACF, this will impact the overall incremental costs. Concentrating on program-
matic costs, we counted only the costs of diagnosis and treatment in the public sector, and not
the private sector. Moreover, new second-line regimens introduced in 2017 present a range of
possible costs for DR-TB treatment. However, as the focus of the current study is on ACF, for
simplicity we assumed costs and outcomes consistent with currently used regimens (Tables 1
and 3), while performing sensitivity analyses with respect to this assumption. For all unit costs,
for simplicity we assumed uncertainty intervals of ±20%.
For the ACF costs, we assumed that all patients identified through ACF are linked to treat-
ment in the public sector. We focused for simplicity on service costs related to the numbers of
confirmatory tests and patient-months of first- and second-line treatment incurred by the
intervention. In doing so, we are neglecting the ‘intervention costs’ needed to facilitate the
delivery of these interventions (e.g., human resources). As discussed below, these are impor-
tant cost components in any exercise aiming to estimate the full costs of ACF [17]. For the pur-
pose of the present study, however, if these intervention costs are similar for moderate- and
high-accuracy testing, they may not substantially impact a comparison in cost between the
two.
Finally, we tracked the costs of treating false-positive TB diagnoses, as driven by the imper-
fect specificity of the screening and diagnostic tools involved, and the low prevalence of TB
(<5% amongst those with symptoms, even in urban slums). Unnecessary TB treatment carries
heavy societal costs, including avoidable stigma [13], as well as the monetary costs to patients
and households (e.g., travel costs) involved in completing a regimen of TB treatment [18].
Such factors are outside the scope of our current study: Here we focus on unnecessary pro-
grammatic spending on the treatment of false-positive TB, recognising (as discussed below)
that this approach represents only one narrow part of the overall adverse effects of false-posi-
tive treatment [13]. All unit costs are provided in Table 3. Overall, we caution that our esti-
mates should not be interpreted as representing the overall cost of any ACF intervention,
given that they miss these cost components, as well as the implementation costs described
above.
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Sensitivity analysis
To test model sensitivity to alternative screening strategies, we first simulated the impact on
incidence and incremental costs of using prolonged cough for symptom screening, which has
higher specificity and lower sensitivity than the symptom screening strategy used in the main
analysis, any symptom suggestive of TB. For additional sensitivity analyses, as a focal model
output, we calculated the cumulative cases averted between 2020 and 2035 under an assumed
budget of US$20 million, calculating the ratio of cases averted between the high-accuracy and
moderate accuracy scenarios. This ratio offers an estimate of the relative cost efficiency of the 2
approaches. We examined model sensitivity to individual parameters by conducting a partial
rank correlation between this model output and each of the model inputs listed in Table 1. We
additionally evaluated the focal model output under different scenarios: (i) assuming that
smear microscopy can detect 25% and 75% of smear-negative and -positive cases, respectively
(as opposed to 0% and 100% in the main analysis) and (ii) using alternative scenarios for the
burden and management of DR-TB, which can consume a disproportionate share of program-
matic spending. We modelled a scenario consistent with Mumbai, which has a substantially
higher DR-TB burden than the national average. We also modelled a scenario with the adop-
tion of new, more effective, and less costly second-line regimens.
Planning and execution of methods
At the outset of this analysis, the modelling plan focused on the confirmatory test, assuming
the use of ‘any symptom suggestive of TB’ as a screening strategy. Subsequently, our main
adjustment to this initial plan was in response to constructive reviewer comments, on the need
to better understand the influence of the screening algorithm. In response, we incorporated
the additional analysis as described above, on the alternative use of prolonged cough as a
screening strategy. Also in response to reviewer comments, we incorporated the additional
sensitivity analyses described above, for the alternative scenarios for the burden and manage-
ment of DR-TB. Our initial modelling plan otherwise underwent no data-driven changes.
Table 3. Unit (service) costs used in the analysis.










2.26 (1.81–2.71) Table 2 from [50] reports a unit cost of US$1.13 for a single
acid-fast bacillus smear in India. With a minimum of 2 smears
required for diagnosis, we double this cost.
Xpert MTB/RIF 17.53 (14.02–21.04) Table S12 from [49]—difference between unit cost of Xpert
and microscopy is given to be US$16.4.
Treatment (cost per patient-month)
First-line
treatment
2.42 (1.93–2.90) For an average total cost of US$14.5 (US$11.6–US$17.4).
Annex 4 from [28]—provider drug costs for DS-TB in India.
Second-line
treatment
100 (80–120) For an average total cost of US$2,400 (US$1,920–US$2,880) for
the full regimen [28,51].
For simplicity we ignore the ‘new’ second-line regimens, as it is unclear what proportions of patients will be eligible
for the different treatment options. However, in S1 Text we provide a sensitivity analysis with respect to the potential
future uptake of these regimens. To capture uncertainty in costs, we allowed variation by ±20% for each of these cost
components.
DR-TB, drug-resistant tuberculosis; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003456.t003
PLOS MEDICINE Trade-offs between cost and accuracy in active case-finding for tuberculosis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003456 December 2, 2020 9 / 20
Results
Results of model calibration are shown in Fig A in S1 Text. Simulating the ACF interventions,
Fig 2 shows model projections for how epidemiological impact varies with coverage (propor-
tion of the slum population screened per year). The higher the proportion of the slum popula-
tion being screened each year, the greater the reduction in the prevalent pool of infectious TB;
the impact shown in Fig 2 is the result of reducing opportunities for transmission in this way,
measuring impact as the percentage reduction in cumulative incidence between 2020 and
2035. The figure illustrates that high-accuracy testing would have a greater impact than a mod-
erate-accuracy strategy, at a given level of coverage, as a result of its higher sensitivity. Even
with the latter diagnosing the most infectious cases, this difference in impact is robust to
parameter uncertainty. Taking the example of 50% coverage, the relative impact of the high-
versus moderate-accuracy strategies is 1.16 (95% credible interval 1.11–1.22).
Fig 3 illustrates how impact varies with incremental spending between 2020 and 2035
under the 2 ACF strategies. Here we assume an illustrative slum population of 2 million peo-
ple, based on the mean population of major cities in India of approximately 10 million, of
whom roughly a third live in slums [19] (for smaller or larger cities, incremental spending will
Fig 2. Active case finding (ACF) impact as a function of coverage. Here we measure impact as the percentage
reduction in cumulative incidence between 2020 and 2035, and coverage as the proportion of the slum population
being screened per year. We assume for simplicity that a randomly selected proportion of the slum population is
selected for screening each year, independent of screening in previous years. An ACF intervention with symptom
screening is followed by bacteriological confirmation, using either a smear-like test (red curve) or an Xpert-like test
(blue curve). The shaded areas represent the 95% credible intervals. Each of the curves is generated by taking a range of
annual screening proportion from 0 (no ACF) to 1 (whole slum population screened for symptoms once a year): The
upper endpoints of each curve occur at the upper limit of this range. Overlap between these areas does not imply a lack
of significant difference between the interventions, as points in the red and blue areas are correlated. Indeed, the
relative impact of the 2 strategies is robust to this parameter uncertainty (see main text).
https://doi.org/10.1371/journal.pmed.1003456.g002
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be proportional to population size). The vertical dashed line shows the percent of cases that
could be averted under an illustrative spend of US$20 million. As noted above, this spend
relates only to service costs of ACF, and does not reflect the full implementation costs of ACF.
Under this budget, the impact of high-accuracy testing, relative to that of moderate-accuracy
testing, is 1.14 (95% credible interval from simulation 0.75–1.99). Overall, therefore, results
suggest that high-accuracy testing would not only be more impactful at a given level of cover-
age (Fig 2), it could—under certain circumstances—also be more cost-efficient.
Fig 4 shows analysis to better resolve these circumstances. Fig 4A shows the most influential
model parameters in the relative impact of a high- versus moderate-accuracy test at a budget
of US$20 million, highlighting the respective specificities of the 2 tests as the most influential
parameters. In particular, the difference in specificity between the 2 tests is an important
driver: Fig 4B shows the absolute difference, plotted against relative impact, highlighting that a
high-accuracy test would be robustly more cost-efficient than a moderate-accuracy one, as
long as it has specificity that is at least 3 percentage points greater.
Fig 5 illustrates why specificity is a driving factor, as well as identifying additional drivers in
the impact of a high-accuracy test. Taking the example of 50% coverage, the figure shows the
separate components of incremental cost through time for both diagnostic tests. Fig 5A illus-
trates that false-positive treatment is by far the largest cost driver of a moderate-accuracy ACF
intervention, followed by the cost of second-line treatment. For a high-accuracy test (Fig 5B),
Fig 3. Active case finding (ACF) impact as a function of incremental programmatic spending, in an assumed slum
population of 2 million people. As in Fig 2, we measure impact as the percent cases averted by ACF. Incremental
spending (in millions of US dollars [USD]) is the overall service cost of diagnostics and treatment, relative to a baseline
scenario of no ACF, and assuming current conditions continue indefinitely. The vertical dashed line shows an
illustrative budget of US$20 million; in spite of using a lower-cost test, a moderate-accuracy strategy is overall less cost-
efficient than a high-accuracy one. The shaded areas represent the 95% credible intervals.
https://doi.org/10.1371/journal.pmed.1003456.g003
PLOS MEDICINE Trade-offs between cost and accuracy in active case-finding for tuberculosis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003456 December 2, 2020 11 / 20
major cost drivers are the cost of the test itself, the cost of treating false-positive diagnoses, and
the cost of second-line treatment. Two comparisons bear mention. First, the rate of false-posi-
tive TB diagnosis is strongly affected by the specificity of the confirmatory test, with a moder-
ate-accuracy test being associated with 350,000 false-positive treatment initiations (95%
credible interval 100,000–710,000), compared to 180,000 for high-accuracy testing (95% credi-
ble interval 30,000–560,000). Second, the effects of each test on DR-TB incidence plays an
important role in cost dynamics: By identifying DR-TB cases early, high-accuracy testing
tends to have a stronger impact on reducing DR-TB incidence, thus leading to cost savings in
second-line treatment costs, over 15 years.
Cost drivers are further explored in Fig 6. The role of false-positive TB treatment is illus-
trated in Fig 6A, which shows how the positive predictive value of the whole diagnostic algo-
rithm (including symptom screening) changes over time under both algorithms. For both
scenarios, this value substantially decreases over time as a result of decreasing TB prevalence
in the community but remains considerably lower for smear microscopy than for Xpert. Like-
wise, the role of DR-TB is further illustrated in Fig 6B, which shows the strong DR-TB inci-
dence reductions that would be brought about by a high-accuracy testing strategy over time.
The cost efficiency of the overall ACF algorithm can be shaped as much by the choice of
screening algorithm as by the choice of confirmatory test. Fig B in S1 Text shows results for
incidence and impact under an alternative screening algorithm, using prolonged cough as the
eligibility criterion for confirmatory testing, an approach having lower sensitivity and higher
specificity (25% and 96%, respectively [14]). At a given level of coverage, such a screening
approach would reduce the overall impact of both high- and moderate-accuracy strategies,
Fig 4. Sensitivity analysis to identify key model parameters in the relative impact of high- versus moderate-accuracy strategies, under a given budget of US$20
million between 2020 and 2035. Here, we define relative impact as the ratio of the number of cases averted over this period by a high-accuracy testing strategy relative
to a moderate-accuracy one. In Fig 3, this focal model output is estimated to be 1.14 (95% credible interval from simulation 0.75–1.99). (A) Partial rank correlation
coefficients of model parameters against relative impact, showing only the 10 highest correlations, and highlighting the test specificities as being the 2 most influential
parameters. (B) Association between relative impact and test specificity, showing that rather than individual specificities, it is their absolute difference that matters most
for relative impact. All points to the right of the vertical dashed line correspond to a high-accuracy test being more impactful than a moderate-accuracy one; these results
suggest that an absolute specificity difference of at least 3 percentage points is sufficient to ensure that a high-accuracy test is more impactful than a moderate-accuracy
one. DR-TB, drug-resistant tuberculosis; DS-TB, drug-susceptible tuberculosis; USD, US dollars.
https://doi.org/10.1371/journal.pmed.1003456.g004
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owing to its lowered sensitivity. As a result of its higher specificity, such an approach also sub-
stantially reduces the number of false-positive treatments overall, narrowing this specific
advantage of a high-accuracy test. However, under a given budget of US$20 million (as used in
Fig 4), a prolonged cough screening algorithm could allow many more people to be screened
over time, potentially leading to a greater impact overall (Table A and Fig B in S1 Text) than
that shown in Fig 3. In turn, this enhanced impact promotes the long-term effect of the high-
accuracy test in averting second-line costs. The overall effect is for the relative impact of the 2
testing strategies at a budget of US$20 million, to remain qualitatively similar to that estimated
from Fig 3 above, and indeed shifted in favour of the high-accuracy test.
Finally, we conducted sensitivity analyses. Focusing on the relative impact of the high- ver-
sus moderate-accuracy strategies shown in Fig 3, Fig D in S1 Text shows how this focal model
output varies under a range of scenarios. The figure illustrates that the essential qualitative
results remain under alternative scenarios for the sensitivity of smear microscopy, the burden
and management of DR-TB, and the size of the NTS population.
Discussion
ACF is potentially highly impactful, but also highly resource-intensive: Our analysis therefore
addresses the critical need to optimise its cost-effectiveness. We used mathematical modelling
to examine strategies for microbiological testing in ACF for TB, aiming to identify the type of
confirmatory test that would yield the greatest epidemiological impact at the lowest cost.
Findings
We hypothesised that a moderate-accuracy testing strategy, using a relatively cheap test that
can nonetheless detect the most infectious cases, may be more cost-efficient (achieving
Fig 5. Breakdown of the incremental ACF service cost, shown here at 50% screening coverage for the 2 ACF algorithms. (A) Moderate-accuracy testing. The major
driver of the incremental cost of moderate-accuracy testing is the treatment of false-positive TB in the non-TB symptomatic population (orange line). (B) High-accuracy
testing. Notably, the cost of treatment of false-positive individuals is nearly halved when using an Xpert-like test for diagnosis (orange line). False-positive TB treatment
costs and diagnosis costs (red line) are the 2 components that are the main cost drivers for high-accuracy testing. The shaded areas represent the 95% credible intervals.
ACF, active case finding; TB, tuberculosis; Tx, treatment; USD, US dollars.
https://doi.org/10.1371/journal.pmed.1003456.g005
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incidence reductions at lower cost) than a high-accuracy strategy. However, our results suggest
that the converse is true (Fig 3) wherever lower test cost is associated with reduced specificity.
The reasons are 3-fold: (i) small improvements in test specificity can translate to large reduc-
tions in unnecessary (false-positive) TB treatments, which outweigh the cost of the test; (ii) a
high-accuracy test that can also identify rifampicin resistance can offer long-term savings by
reducing the burden of rifampicin-resistant TB (and thus the need for costly second-line treat-
ment); and (iii) a high-accuracy test has a greater impact than a moderate-accuracy test as a
result of its higher sensitivity (Figs 2–4).
We have conservatively designated the confirmatory tests as ‘smear-like’ and ‘Xpert-like’, in
recognition that performance data drawn from meta-analyses of clinical trials (Table 1) do not
necessarily reflect the numbers of appropriate or erroneous TB treatments that would arise in
real-world ACF implementation. In light of this uncertainty, the key conclusion of our analysis
is not that one test should be preferred over another, but rather that specificity in field ACF
conditions—for any diagnostic test—is a critical data gap to address for future ACF planning.
In recent years the availability of molecular diagnostics has rapidly expanded for routine TB
services in India [20–22]; our findings support the use of similar tests, with equal or higher
specificity and the ability to detect rifampicin resistance, in ACF.
Quantifying specificity
We note that quantifying ‘true’ specificity is a complex challenge, partly as the culture refer-
ence standard (against which specificity is judged) also has imperfect sensitivity, raising the
question of how to interpret smear-positive, culture-negative results, particularly amongst
Fig 6. Additional comparisons between testing strategies. (A) Comparison of the positive predictive value (PPV) of active case finding (ACF) strategies. The panel
shows the PPV of the entire diagnostic algorithm (including symptom screening), and not just that of the confirmatory test. Percentages on the right-hand side of the
figure (20%, 50%, etc.) show ACF coverage scenarios, i.e., the proportion of the slum population being screened per year. The shaded areas represent the 95% credible
intervals. Overall, as tuberculosis (TB) prevalence is reduced over time by ACF, the PPV also decreases. Improved diagnostic algorithms, with improved specificity, may
be needed in these advanced stages. (B) Comparison of both testing strategies shown in Fig 3, by their impact on the incidence of drug-resistant TB (DR-TB) over time,
at fixed 50% coverage. Because a high-accuracy test is able to diagnose rifampicin resistance at the point of TB diagnosis, it can contribute strongly to long-term
reductions in DR-TB incidence, thus also averting future costs of second-line treatment (Fig 5B). A moderate-accuracy strategy also leads to a decline in DR-TB
incidence, although to a lesser extent, as individuals with DR-TB are only switched to second-line therapy after failing first-line therapy.
https://doi.org/10.1371/journal.pmed.1003456.g006
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those with strong clinical signs of TB. As initial steps in this direction, future ACF implementa-
tion research could aim, for example, to supplement microbiological reference standards with
‘composite’ reference standards that additionally incorporate clinical diagnosis and patient
assessment on follow-up, including response to anti-TB treatment. Our results also have impli-
cations beyond the particular diagnostic tests being examined here. For example, a new gener-
ation of molecular diagnostic test, Xpert Ultra, has higher sensitivity than Xpert, but also lower
specificity [6]. Its use in ACF would lead to similarly unacceptable numbers of false-positive
TB treatments, as those illustrated in Fig 5A.
Role of screening
Our sensitivity analysis shows that the performance of the screening stage can also play an
influential role, although whether this widens or narrows the gap between the 2 diagnostic
tests (at a given budget) depends on the relative magnitudes of (i) the reduction in false-posi-
tive TB treatments arising from a higher-specificity screening algorithm and (ii) the long-term
second-line TB treatment costs that can be averted by a high-accuracy test (Fig C and Table A
in S1 Text). In our current work, the overall effect is for our qualitative findings to remain
unchanged. Strategies such as X-ray screening (not modelled in the current study) can show
greater sensitivity and specificity than symptom screening alone [23], while allowing TB detec-
tion amongst those not reporting symptoms. Implementation of X-ray screening is more
resource-intensive than symptom screening, but could be facilitated by the use of mobile radi-
ography units [24,25], along with newly emerging technology for automated X-ray reads
[26,27]. While the present analysis has focused on confirmatory tests, a more systematic explo-
ration of these and other screening strategies will be an important area for future work.
The patient perspective
Focusing on programmatic costs, our analysis does not address the important issue of patient
costs associated with TB [28–30]. In the context of routine TB services, the costs of care-seek-
ing and TB treatment can have a substantial impact on productivity and household income,
and are an important cause of catastrophic health expenditure [29]. Previous work in India has
shown that ACF can bring about substantial reductions in these patient costs [18], essentially
by bringing TB services to those in need in a timely way. By neglecting patient costs, our analy-
sis therefore does not capture the societal cost savings that would result from higher-sensitivity
testing strategies. Our analysis also does not address the societal costs of false-positive TB diag-
nosis, including the potentially life-changing impact of stigma [13] and the potential side
effects of TB treatment. Our analysis thus does not capture the societal cost savings that would
result from higher-specificity ACF approaches. Overall, therefore, we expect that inclusion of
societal costs would act to widen the gap between the strategies shown in Fig 3. The extension
of our analysis to incorporate these important costs to the patient is an important area for
future work.
Key considerations in intervention costs
Our study has focused on the performance of confirmatory tests in ACF but has not addressed
the implementation of these tests. For example, the overall cost of an Xpert test will depend on
whether Xpert units are readily accessible for use in ACF, or whether they are only available in
central laboratories, requiring the additional expense of sample transport and relaying test
results to the patient. Previous work has addressed these considerations in the context of rou-
tine TB services [31]. Although such considerations are outside the scope of our current analy-
sis, we note that access to Xpert facilities is likely to be a more pressing concern in peripheral
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health facilities in rural India than in urban slums. India’s current National Strategic Plan
includes measures to improve the capacity for Xpert testing nationwide [32]. Moreover,
recent developments offer prospects for reduced reliance on laboratory infrastructure, for
example with the development of new, more mobile molecular diagnostics such as Xpert
Omni [33] and Truenat [34], as well as the deployment of Xpert MTB/RIF through mobile
diagnostic vans [35]. All of these developments would tend to reduce the per-test cost of
high-accuracy diagnostic tools, by allowing closer proximity of testing to the ACF interven-
tion. For any study aiming systematically to estimate the full cost of ACF, these and other
implementation factors will be important to take into account (e.g., as demonstrated in
[17,31]). Nonetheless, our findings illustrate an important consideration in any such study:
In addition to these important cost components, the specificity of the confirmatory test,
along with that of the whole ACF cascade, is likely to be a key driver of the cost/impact ratio
of any ACF intervention.
Our analysis has ignored intervention costs directly associated with the rollout of the inter-
vention, such as human resource costs and costs associated with the purchase of equipment.
We also take a simple approach of assuming unit costs that are unaffected by the scale of the
intervention, thus ignoring the potential for economies of scale, especially at high levels of pop-
ulation coverage. If human resource costs are similar under the 2 strategies, they would have
little effect on the relative costs of these strategies. Overall, however, we emphasise that our
estimates should not be interpreted as estimates of the actual cost of ACF. An important area
for future work would be to incorporate these important elements [17,36], for more compre-
hensive estimates of the full cost of ACF.
Model limitations
For simplicity, we ignored pre-treatment loss to follow-up. Although commonly observed in
practical implementations of ACF [37], we do not expect this simplification to alter our essen-
tial findings, as long as it affects the 2 testing strategies roughly equally. Again, for simplicity,
we assume that all false-positive TB diagnoses have the same rates of treatment completion as
true-positive diagnoses; if their completion rates are substantially lower, this would tend to
reduce the treatment cost associated with false-positive TB diagnosis. Finally, we note that
there is considerable uncertainty about the potential transmission impact of ACF interven-
tions, owing partly to a lack of direct evidence, particularly in South-Asian settings [4]. In the
present analysis, our impact projections are based on a series of assumptions, including perfect
implementation of symptom screening and diagnosis, high-quality engagement with and par-
ticipation by the community, effective linkage to treatment, immediate rapid bacteriological
suppression upon treatment (thus interrupting transmission), and assumptions about the
degree to which ACF is able to identify TB cases while they still have substantial potential for
passing on infection [4]. Lessons from current and future ACF initiatives will be invaluable in
identifying which of these assumptions needs most attention.
Conclusion
As ACF efforts are scaled up in India and other high-burden settings, implementation plan-
ning could benefit from a population perspective of potential costs and benefits. Such a per-
spective, complementing other approaches such as operational research, takes into account
both the epidemiological impact and unintended consequences (such as false-positive diagno-
sis) of large-scale deployment. Addressing important questions about the optimum implemen-
tation of ACF could open the way for considerable impact on TB burden, in India and
elsewhere.
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